---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-24-000683"
form_type: "8-K"
ticker: "LNAI"
cik: "0001527728"
company_name: "Lunai Bioworks Inc."
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T07:57:19.691948+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# RenovaroCube to acquire remaining 25% of Cyclomics for 100% ownership in cancer diagnostics

## Summary
- RenovaroCube amends LOI to acquire full 100% ownership of Cyclomics (was 75%).
- Deal strengthens AI-driven early cancer detection; combines CyclomicsSeq and OmniOmics 4th-gen tech.
- Collaborations with Oxford Nanopore and Nvidia provide sequencing, supercomputing, and AI software.
- Technology aims to detect a single ctDNA molecule in blood with nearly 100% accuracy.
- RenovaroCube's Cube platform has over 3,600 biomarker panels for 13 cancers.

## SEC filing metadata
- accession: 0001731122-24-000683
- form_type: 8-K
- ticker: LNAI
- cik: 0001527728
- company_name: Lunai Bioworks Inc.
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527728/000173112224000683/0001731122-24-000683-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527728/000173112224000683/e5618_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-24-000683
- JSON: https://secwatch.observer/filing/0001731122-24-000683.json
- Plain text: https://secwatch.observer/filing/0001731122-24-000683.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.